Utilizing Albumin Value, HALP Score and LCR Value for Predicting Survival in Patients with Pancreatic Adenocarcinoma

Background and Objectives: This study aimed to determine whether albumin levels and the ratios of key biochemical markers, including the hemoglobin, albumin, lymphocyte, and platelet (HALP score) and lymphocyte/C-reactive protein ratio (LCR), can predict survival and recurrence in patients with pancreatic adenocarcinoma. Materials and Methods: A total of 87 patients who underwent surgery for pancreatic adenocarcinoma in our clinic between January 2017 and December 2021 were included. Preoperative albumin levels, HALP scores, and LCR values were calculated and analyzed to evaluate their predictive value for pathological findings in the early postoperative period. Results: The mean age of the study population was 64.8 ± 9.6 years; 59 patients (67.8%) were male, and 28 (32.2%) were female. The cut-off values for HALP, LCR, and albumin were 34.4, 0.61, and 38.55, respectively. Patients with low HALP scores had significantly shorter overall survival than those with high scores (15.8 vs. 19.3 months; p < 0.01). Similarly, patients with low LCR scores showed shorter survival than those with high scores (17.8 vs. 18.5 months; p < 0.01). High albumin levels were associated with significantly longer survival compared to low albumin levels (16.3 vs. 14.6 months; p < 0.01). Conclusions: Low HALP scores and low albumin levels were identified as significant independent prognostic factors for both disease-free and overall survival in patients with pancreatic adenocarcinoma.